IN THE CLAIMS

This listing of the claims replaces all prior versions of the claims in the application.

1. (currently amended): A method of inducing production of antibodies against a cancer antigen, comprising the step of administering a bispecific antibody to a human patient, said bispecific antibody comprising a first binding site capable of recognizing and binding a first antigen wherein said first antigen is FcγRIII and further comprising a second binding site capable of recognizing and binding a second antigen, in an amount sufficient to induce production of antibodies to said second antigen in said patient, wherein said second antigen is a cancer antigen selected from the group consisting of c-erbB-2, HMW mucin, and HMW mucin II, ~~and p-glycoprotein~~ and further wherein said second binding site comprises a binding site derived from a monoclonal antibody produced by a hybridoma selected from the group consisting of: 452F2 (HB 10811), 741F8 (HB 10807), 759E3 (HB 10808), 454C11 (HB 8484), 788G6 (HB 8692), 200F9 (HB 10791), 697B3 (HB 10806), 120H7 (HB 10790), 203E2 (HB 10799), 254H9 (HB 10792), 245E7 (HB 8489), 2G3 (HB 8491), and 369F10 (HB 8682)~~, and 15D3 (HB 11342)~~.

2. (original): The method according to claim 1, wherein said first binding site is a binding site derived from the monoclonal antibody produced from the 3G8 hybridoma.

3. (original): The method according to claim 1, wherein said second antigen is present in the patient.

4 to 7. (canceled).

8. (currently amended): ~~The~~ A method of inducing production of antibodies against an erbB-2 antigen ~~according to claim 1~~, the method comprising administering a bispecific antibody to a human patient, said bispecific antibody comprising a first binding

site capable of recognizing and binding a first antigen wherein said first antigen is FcγRIII and further comprising a second binding site capable of recognizing and binding a second antigen wherein said second antigen is erbB-2, in an amount sufficient to induce production of antibodies to said erbB-2 antigen in said patient, wherein said bispecific antibody is produced by the hybrid hybridoma CRL 10197.

9 to 15. (canceled).